Pfizer Inc. reported strong third-quarter 2024 earnings, with total revenues reaching $17.7 billion, reflecting a 32% operational growth. Non-COVID products grew by 14% to $13.6 billion. The company surpassed Wall Street expectations and raised its full-year guidance due to increased demand for its COVID-19 medications. Meanwhile, Merck & Co. also reported its third-quarter 2024 financial results, beating earnings estimates with strong sales of its cancer drug Keytruda, which saw a 21% growth to $7.4 billion. Merck's earnings beat estimates by $0.07, and revenue topped estimates. However, Merck lowered its full-year sales guidance due to declining demand for its Gardasil vaccine in China, which is expected to continue into 2025. EPS factoring BD was also considered in the guidance.